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Abstract
Background: Currently, resection criteria for colorectal cancer liver metastases (CRCLM) are only limited
by remnant liver function. Morbidity and survival after a partial hepatectomy with limited or extended
indication criteria were compared.
Methods/Design: Between 1991 and 2010, patients undergoing a liver resection for CRCLM with
limited (n = 169) or extended indication criteria (n = 129) were retrospectively identified in a prospectively
collected single-centre database. Limited indication criteria were defined as less than three unilateral, not
centrally located liver metastases in the absence of extra hepatic metastases. The extended criteria were
only limited by predicted remnant liver volume and patients fitness. Data on co-morbidity, resection
margin, short- and long-term morbidity, disease-free (DFS) and overall survival were compared.
Results: Patients with limited indications had less major complications (19.5% vs. 33.1%, P < 0.01),
longer overall survival of 68.8 months [confidence interval (CI) 46.5–91.1] vs. 41.4 months (CI 33.4–49.0,
P ≤ 0.001) and longer median DFS of 22.0 months [confidence interval (CI) 15.8–28.2] vs 10.2 months (CI
8.4–11.9, P < 0.001) compared with the extended indication group. Cure rates, defined as 10-year DFS,
were 35.5% and 15.8%, respectively. Fewer patients in the extended indication group underwent an R0
resection (92.9% vs. 77.5%, P < 0.001). Only 17% of all R1 resected patients had recurrences at the
transection plane.
Conclusion: A partial hepatectomy for CRCLM with extended indications seems justified but is asso-
ciated with higher complication rates, earlier recurrence and lower overall survival compared with limited
indications. However, the median 5-year survival was substantial and a cure was achieved in 15.8% of
patients.
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Introduction
During the last decade, the limited criteria for a partial liver
resection have been replaced by more extended indication criteria.
Improvements in surgical technique, optimization of peri-
operative care, improvements in diagnostic imaging, pre-operative
liver remnant volume modulation and effectiveness of modern
chemotherapy regimens have boosted the widening of resectability
criteria. Traditionally, only patients with a maximum of three
colorectal cancer liver metastases, located peripherally at one side
of the liver with an anticipated resection margin greater than
10 mm and without signs of extrahepatic disease were considered
eligible for a partial liver resection.1–4 Based on these limited
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criteria,only 10–20% of patients with colorectal cancer liver metas-
tases were eligible for a resection. Recent studies have shown that a
liver resection in patients with multiple and/or bilateral colorectal
liver metastases results in overall 5-years survival rates between
23% and 51%.3,5 Moreover, centrally located liver metastases are no
longer a contraindication for liver surgery. In patients with a
normal functioning liver, extended hemihepatectomies can be per-
formed safely and mesohepatectomy or a central liver resection is
an alternative for an extended hemihepatectomy when parenchy-
mal loss needs to be minimized.6 If resectable extrahepatic metas-
tases are present, a resection can be offered with 5-year overall
survival rates up to 28%.6,7 Thus, liver resection criteria for
colorectal cancer liver metastases (CRCLM) are at present only
limited by an anticipated R0 status and an adequate functional liver
remnant. Patients in good general health, with technically
resectable metastatic disease limited to the liver, regional lymph
nodes or/and lungs, are considered for resection regardless of
associated clinical predictive factors.8–10
Parallel to the expanding indications for a liver resection new
strategies to improve resectability have also been popularized.11–13
A liver resection combined with ablation of metastases14–16 and/or
induction chemotherapy to reduce the hepatic tumour size or
tumour load may render unresectable metastases resectable or
may help reduce the extent of liver resections.17 Staged resections,
with or without portal vein embolization/ligation, can be used for
a two-step clearance of liver metastases, to increase future
remnant liver volume and to achieve a definitive R0 status.
Expanding the indications and application of the aforemen-
tioned strategies has increased the number of patients becoming
resectable.18 The objective of the present study was to evaluate the
post-operative clinical outcome and long-term survival in
patients undergoing a liver resection for colorectal cancer liver
metastases based on limited compared with extended indications.
Material and methods
Patients
A prospective database became operational in the Maastricht Uni-
versity Medical Centre HPB unit in 2001. All patients that under-
went liver surgery before this date were included retrospectively.
Patients undergoing liver surgery for CRCLM between 1991 and
2010 were included in the present study and assigned to a group
with limited indication criteria or a group with extended indica-
tion criteria for resection. Patients were staged using a four-phase
contrast enhanced abdominal CT scan. All patients with either
primary or secondary liver tumours were discussed at a multidis-
ciplinary liver meeting. Patient-specific co-morbidities and diag-
nostic procedures were assessed and the definitive treatment
strategy was decided in consensus. Induction chemotherapy in
irresectable patients, a liver resection combined with tumour abla-
tion, pre-operative portal vein embolization, liver first policy in
rectal cancer and a repeat hepatectomy were all among potential
surgical strategies. Obviously some of these strategies became
available only in more recent years. Vascular reconstructions were
occasionally used. In recent years, patients not undergoing liver
surgery were assigned to stereotactic radiotherapy, percutaneous
tumour ablation, Y90- selective internal radiotherapy or palliative
chemotherapy.
Study groups
Pre-operative CT-, MRI- or PET-CT-scans were used to determine
the number and location of liver metastases. Operation notes gave
insight in the specific type of resection, relation of metastases to
the transection line, duration of surgery, the amount of blood loss
and complications during surgery. Patients were, using predefined
criteria, retrospectively assigned to either the extended indications
group or to the limited indications group. Criteria for limited and
extended indications are depicted in Table 1. Only patients with
colorectal cancer liver metastases and a follow-up of at least 6
months were included in the present study.
Liver resections
All liver resections were classified in accordance with the IHPBA
Brisbane nomenclature (Table 2).19 A liver resection was per-
formed as described previously.20 To determine the definitive
extent of hepatic metastases and transection line, intra-operative
ultrasound was used routinely.
Peri-operative care
In February 2005, the Enhanced Recovery After Surgery (ERAS®)
fast track peri-operative care programme was introduced in liver
surgery at our centre. This programme enhances post-operative
recovery and as a consequence reduces hospital length of stay
(LOS).21 Before the introduction of the ERAS programme there
was no standard peri-operative care protocol.
Oncological follow-up
Follow-up consisted of outpatient visits with plasma
carcinoembryonic antigen levels, every 3 months, and liver
imaging twice in the first 2 years and annually up to 5 years after
surgery. The median follow-up was 33 months (range, 0–235). In
case of recurrence, patients were assessed with PET-CT and the
indication for repeat liver or lung surgery was discussed in the
multidisciplinary oncology meeting.
Table 1 Indication criteria for resection of colorectal liver metastases
Limited indication criteria Extended indication criteria
1. Three or less liver metastases 1. Four or more liver metastases
2. Located at one side of liver
only
2. Bilateral metastases
3. No signs of extra hepatic
metastases
3. Presence of resectable extra
hepatic metastases
4. Anticipated resection margin
more than 10 mm.
4. Centrally located metastases
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Table 2 Clinical characteristics
Variables No. of patients P
All
patients
Limited indication
criteria
Extended
Indication criteria
N = 298 N = 169 N = 129
Patient characteristics
Median age [range], y 64 [24–88] 64 [28–88] 64 [24–82] 0.183
Gender, male (%) 177 (59.4) 110 (65.1) 67 (51.9) 0.022
Co-morbidities, present (%) 100 (33.6) 56 (33.1) 44 (34.1) 0.860
ASA classification
Percentage with ASA 1 12.9 11.2 14.8 0.488
Percentage with ASA 2 60.8 59.2 62.5 0.604
Percentage with ASA 3 26.3 29.6 22.7 0.270
Primary tumour
Location, colon (%) 177 (59.4) 98 (58.0) 79 (61.2) 0.571
AJCC T-stage, T3/T4 disease (%) 87.9 84.8 92.0 0.082
Nodal status, positive nodes (%) 65.9 64.6 67.6 0.618
Hepatic metastases
Median size of largest lesion [range], cm 3.0 [0.0–20.0] 3.0 [0.4–13.0] 3.0 [0.0–20.0] 0.877
Larger than 5 cm (%) 18.7 17.6 20.2 0.622
Median number [range] 2 [1–12] 1 [1–3] 4 [1–12] <0.001
Bilateral metastases (%) 74 (24.8) 0 74 (57.4) –
Concomitant extrahepatic disease (%) 30 (10.1) 0 30 (23.3) –
Pre-operative management
Pre-operative chemotherapy (%) 42.1 34.5 52.0 0.003
Operative details
Two-stage procedure planned 14 0 14 –
PVE during first stage 9 0 9 –
Second stage performed 10 0 10 –
Combined procedure (%) 13 (4.2) 7 (4.1) 6 (4.3) 0.940
Liver first procedure (%) 26 (8.4) 11 (6.5) 15 (10.8) 0.573
Type of liver resection (%)
Major (> 3 segments) 174 (56.5) 81 (47.9) 97 (69.8) <0.001
Left hemihepatectomy 18 (5.8) 9 (5.3) 9 (6.5) 0.669
Right hemihepatectomy 103 (33.4) 55 (32.5) 48 (34.5) 0.713
Left extended hemihepatectomy 4 (1.3) 0 (0.0) 4 (2.9) –
Right ext. hemihepatectomy 12 (3.9) 2 (1.2) 10 (7.2) 0.007
Central liver resection 15 (4.9) 0 (0.0) 15 (10.8) –
≤1 segmentectomy or (multi) metastasectomy 91 (29.5) 65 (38.5) 26 (18.7) <0.001
Multisegmentectomies (≥ 2) 64 (20.8) 38 (22.5) 26 (18.7) 0.416
Only PVE 1 (0.3) 0 (0.0) 1 (0.7) –
Concomitant local ablation* (%) 10 (3.2) 1 (0.6) 9 (6.7) 0.004
Post-operative management
Percentage with post-operative chemotherapy 37.2 36.6 37.8 0.841
ASA, American Society of Anesthesiologists; PVE, portal vein embolization.
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Outcome parameters
The primary endpoint of the study was overall survival. Secondary
endpoints were all complications: a liver surgery-specific compo-
site endpoint,22 readmissions, post-operative mortality, hospital
LOS and disease-free survival (DFS). Complications were regis-
tered daily using National Surgical Adverse Event Registration
(LHCR) software23 of the Dutch Association of General Surgery
before 2009 and in the hospital information system (SAP,
Walldorf, Germany) thereafter. The post-operative course of all
discharged patients was discussed at the surgeons’ morning
meeting and the Clavien–Dindo classification was used to grade
complications after surgery.24 Complications with a Clavien–
Dindo score ≤2 were considered minor complications whereas
complications ≥3a were considered major complications. Patient
demographics were also registered and information on co-
morbidity, location and TNM stage of the primary tumour and
moment of occurrence of liver metastases were retrieved from
patient charts. Size of the metastases and the resection margins
were retrieved from pathology reports. R0 resections were defined
as resections with a tumour-free resection surface. If invasion in
the resection surface was present, the resection was considered R1.
R1 resections with metastases reaching the resection surface were
analysed separately for local recurrences and survival.
Overall survival (OS) and DFS after a liver resection were reg-
istered in months and calculated in percentages. Overall survival
was calculated as the time period between the date of diagnosis
and death. In the case of two-stage hepatectomies, DFS was cal-
culated as the time period between the first stage operation and
the recurrence of metastases after the second stage operation.
Statistical analysis
Data were analysed using SPSS version 18.0 (SPSS Inc., Chicago,
IL, USA). Data are expressed as median and percentages or sur-
vival in months [95% confidence interval (CI)]. The chi-square
test was used to analyse categorical data whereas continuous data
were analysed using the t-test U-test. The time to recurrence and
OS were calculated with the Kaplan–Meier (sensored) method
using the date of liver surgery and date of diagnosis, respectively,
as a reference date. A level of P < 0.05 was considered to be
statistically significant.
Results
Patients
In total, 298 patients who underwent 308 liver resections for
CRCLM between 1991 and 2010 were included. Ten patients had
a two-stage strategy. Explorations with irresectable disease at lapa-
rotomy (n = 6) were excluded from further analysis (Fig. 1). In all
patients with repeat resections for recurrent CRCLM (n = 41)
results were analysed with the initial resection as a reference. The
median age was 65 years (range 24–88). A total of 169 patients
were included in the limited indications group compared with 129
patients in the extended indications group. Patient demographics,
pre-operative characteristics, intra-operative details and pathol-
ogy details are presented in Tables 2 and 3. Co-morbidities were
present in 33.6% of patients, predominantly cardiovascular
disease (28.2%), diabetes mellitus (7.7%) and pulmonary disease
(4.0%). As expected through the allocation of patients, patients
with extended indications had a more extensive spread of meta-
static disease as is evidenced by the number of metastases, number
of patients with bilateral disease and with concomitant extrahe-
patic disease. These patients underwent extended hepatectomies
more often compared with the limited indications group (10.1%
vs. 1.2%, P < 0.001). Surgical procedures are depicted in Table 2.
Pathological analysis
The percentage of R0 resections was 92.9% in the limited indica-
tions group and 77.5% in the extended indications group
(P < 0.001).
Maastricht University Medical Center (Nov 1991−
Dec 2010). Total no. of explorations for CRCLM/patients
N = 352/304
Explorations/patients excluded N = 44/6:
- No resection or PVE exclusively: N = 6/6
- Cryo ablation N = 2/2
- Peritoneal metastases N = 2/2
- No metastases N = 1/1
- PVE exclusively N = 1/1
- Repeat resections for recurrence:
N = 38/34 patients
Remaining no. of liver resections/patients
N = 308/298 patients
(10 two-stage hepatectomies)
Limited indication criteria
N = 169/169
Extended
indication criteria
N = 139/129
(10 two-stage hepatectomies)
Figure 1 Flowchart study population. PVE, portal vein embolization
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Surgical outcome
There were no significant differences in blood loss during surgery,
length of hospital stay and number of readmissions between both
the groups. However, there was a significant difference in the
median operation time 205 [75–660] min in the limited indica-
tions group compared with 240 [85–660] min in the extended
indications group (P < 0.001; Table 3). Major complications
occurred in 19.5% of the patients with limited indications com-
pared with 33.1% of the patients with extended indications (P =
0.007). The 90-day post-operative mortality rate was 3.6% in the
limited indication group compared with 5.0% in the extended
indications group (P = 0.519; Table 4).
Overall survival
The median OS for all patients was 55.9 months (CI 48.5–63.3)
with a 5-year OS rate of 48.3%. Patients in the limited indications
group had a median OS of 68.8 months (CI 46.5–91.1) with a
5-year OS rate of 60.5%. Patients in the extended indications
criteria group had a median OS of 41.2 months (CI 33.4–49.0)
and a 5-year survival of 33.2% (P < 0.001). Ten-year OS rates in
the limited indications group and the extended indications group
were 35.5% and 15.8%, respectively.
365-day mortality
During the first post-operative year a steep drop in survival was
observed in the Kaplan–Meier curve (Fig. 2) in both groups. We
selected a group of all patients that died within 1 year after a
partial hepatectomy and compared multiple patient characteris-
tics with a group of all patients that survived at least 1 year. The
only significant difference between the group that died within 1
year and the group that survived at least 1 year was age (median
67.7 [28.6–86.1] years and 63.7 [24.2–88.2], respectively and P =
0.025). Three more factors were borderline significant: combined
oncological procedures, primary tumour positive lymph nodes
and an American Society of Anesthesiologists’ (ASA) score of 3.
9.5% of the patients that died within 1 year had a liver resection
combined with a resection of the primary tumour compared with
3.6% of the patients that survived more than 1 year, P = 0.077.
Moreover, 77.5% of the patients that died within 1 year had
primary colorectal positive lymph nodes compared with 63.7% of
the patients surviving more than 1 year, P = 0.091. Finally, 44.4%
of the patients that died within 1 year were considered ASA 3
whereas only 24.6% of the patients that survived more than 1 year
were considered as ASA 3, P = 0.069.
Disease-free survival
The median DFS for all patients was 15.7 months (CI 12.8–18.7)
with a 5-year DFS rate of 23.7%. Patients in the limited indica-
tions group had a median DFS of 22.0 months (CI 15.8–28.2) and
a 5-year DFS rate of 30.5%. Patients in the extended indications
group had a median DFS of 10.2 months (CI 8.4–11.9) and a
5-year DFS rate of 14.2% (P < 0.001). Kaplan–Meier curves of
both OS and DFS are presented in Figs 2 and 3.
Thirty-three patients with a hepatic recurrence underwent a
repeat liver resection. 14% of these patients did not suffer a recur-
rence during follow-up. 86% of patients, 82% in the limited indi-
cations group and 92% in the extended group, developed a second
recurrence. The median time from the repeat resection to the
Table 3 Comparison of surgical details, pathological details and hospital length of stay (LOS)
Variables No. of resections / patients P
All resections /
patients
Limited
indication criteria
Extended
indication criteria
N = 308 / 298 N = 169 / 169 N = 139 / 129
Operative details
Median estimated blood loss [range], ml 800 [10–11600] 775 [10–10000] 800 [50–11600] 0.592
Median duration of operation [range], min 217 [75–660] 204.5 [75–660] 240 [85–660] <0.001
Pathology
Resection margin,
Patients with R0 resections 257 (86.2) 157 (92.9) 100 (77.5) <0.001
Patients with R1 resections 41 (13.8) 12 (7.1) 29 (22.5) <0.001
Patients with R2 resections 0.0 0.0 0.0 –
Hospital LOS
Median LOS [range], days 8 [2–120] 8 [3–92] 8 [2–120] 0.579
Readmissions
Number of patients readmitted (%) 30 (9.7) 14 (8.3) 16 (11.5) 0.342
Repeat resections
Number of patients undergoing repeat resections for recurrence (%) 33 (11.1) 21 (12.4) 12 (9.3) 0.190
Number of patients with recurrence without resections (%) 122 (40.6) 62 (36.7) 60 (46.5) 0.190
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second recurrence was 8.7 [0.0–18.9] months and 6.9 [1.9–11.9]
months (P = 0.390) in both groups, respectively.
Recurrence after R1 liver resections
On histological examination, the resection specimen of 41
patients (13.3%) showed a microscopically positive resection
margin (R1 resection). In these patients, recurrence of metastases
in any location (i.e. liver and elsewhere) occurred in 23 (56%) out
of 41 patients. Thirteen (32%) of these patients developed hepatic
recurrence of which 3 (7%) had both intra- and extrahepatic
recurrence. Only seven (17%) of patients with an R1 resection
recurred at the former R1 resection surface: one patient in the
limited indications group and six in the extended indications
group. Ten (24%) patients showed extra hepatic recurrence only.
Eighteen (44%) patients with an R1 resection stayed disease free
during the follow-up period (median follow-up was 33.3 [0.2–
165.9] months) (figure 4).
Overall survival in all patients with an R0 resection was 60.0
[53.0–67.0] months with a 5-year survival rate of 50.4%. Patients
with an R1 resection showed a median OS of 44.3 [26.3–62.4]
months and a 5-year survival rate of 34.9% (P = 0.040). Disease-
free survival in all patients with an R0 resection was 16.9 [13.9–
Table 4 Complications
Variables No. of resections / patients P
All resections /
patients
Limited indication
criteria
Extended
indication criteria
N = 308 / 298 N = 169 / 169 N = 139 / 129
Complications
Complications present 113 (36.7) 54 (32.0) 59 (42.4) 0.057
Minor complications present 34 (11.0) 21 (12.4) 13 (9.4) 0.392
Clavien–Dindo grade I 10 (3.2) 5 (3.0) 5 (3.6) 0.753
Clavien–Dindo grade II 24 (7.8) 16 (9.5) 8 (5.8) 0.227
Major complications present 79 (25.6) 33 (19.5) 46 (33.1) 0.007
Clavien–Dindo grade IIIa 48 (15.6) 20 (11.8) 28 (20.1) 0.045
Clavien–Dindo grade IIIb 8 (2.6) 2 (1.2) 6 (4.3) 0.085
Clavien–Dindo grade Iva 10 (3.2) 5 (3.0) 5 (3.6) 0.753
Clavien–Dindo grade Ivb 0 (0.0) 0 (0.0) 0 (0.0) –
Clavien–Dindo grade V 13 (4.2) 6 (3.6) 7 (5.0) 0.519
Liver surgery specific composite endpoint (CEP)
Liver surgery-specific CEP 67 (21.8) 29 (17.2) 38 (27.3) 0.031
Ascites 8 (2.6) 2 (1.2) 6 (4.3) 0.085
Post-resectional liver failure 11 (3.6) 4 (2.4) 7 (5.0) 0.209
Bile leakage 16 (5.2) 5 (3.0) 11 (7.9) 0.051
Intra-abdominal haemorrhage 9 (2.9) 4 (2.4) 5 (3.6) 0.524
Intra-abdominal abscess 35 (11.4) 19 (11.2) 16 (11.5) 0.941
90-day post-operative mortality 13 (4.2) 6 (3.6) 7 (5.0) 0.519
Other liver-related complications
Hepatic encephalopathy 5 (1.6) 2 (1.2) 3 (2.2) –
Liver dysfunction 2 (0.6) 0 (0.0) 2 (1.4) –
Cholangitis 2 (0.6) 1 (0.6) 1 (0.7) –
Other complications
Sepsis 9 (2.9) 5 (3.0) 4 (2.9) 0.943
Cardiovascular 13 (4.2) 8 (4.7) 5 (3.6) 0.719
Pulmonary 28 (9.1) 17 (10.1) 11 (7.9) 0.653
Renal / urine tract 12 (3.9) 8 (4.7) 4 (2.9) 0.477
Gastro-intestinal 18 (5.8) 7 (4.1) 11 (7.9) 0.115
Haematological 1 (0.3) 0 (0.0) 1 (0.7) –
Neurological 9 (2.9) 1 (0.6) 8 (5.8) –
Wound infection 7 (2.3) 3 (1.8) 4 (2.9) –
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19.9] months (5-year DFS rate 25.2%) versus 9.4 [3.9–15.0]
months (5-year DFS rate 17.4%) in patients with an R1 resection
(P = 0.091).
Discussion
In this study, short- and long-term outcomes in patients under-
going a liver resection for colorectal cancer liver metastases with
extended indications were assessed and compared with a group of
patients operated according to limited indications criteria. We
showed in the extended indications group a 5-year survival of
33.2% equivalent to a median OS of 41 months. In patients under-
going a liver resection according to the limited indications, a
5-year OS of 60.5% was observed, equivalent to a median OS of 69
months. In the latter group, 5-year DFS was 30.5% equivalent to a
median DFS of 22 months. In patients with extended indications,
5-year DFS was 14.2% equivalent to a median DFS of 10 months,
which is significantly lower than in patients with limited indica-
tions. When patients underwent a repeat liver resection for recur-
rence, the median DFS was prolonged by 8 months. Although the
outcome was worse in the extended indication group, cure of a
cure, defined as DFS longer than 10 years, was observed in 15.8%
of patients.
Recently, short- and long-term outcomes in patients undergo-
ing a liver resection for colorectal cancer liver metastases before
and after 2000 have been published.25 In that study, two time
periods with mixed indication criteria were compared. Although
extended indication criteria were used in the patient groups before
and after 2000, most patients operated after 2000 were still treated
within the limited indication criteria. This may explain the rela-
tively small difference observed in a 5-year OS of 47% and 58%
between the two groups, respectively, in that study. Outcome
results regarding patients undergoing a liver resection for
colorectal cancer liver metastases within extended indication
criteria are scarce. Recent publications report on the influence
on outcome of only one single component of the former
contraindications, e.g. number of metastases, resection margin or
extra hepatic disease.3,5,7,26
The results of this study are in line with recent publications and
are slightly better than the results of a recently published meta-
analysis of studies on a liver resection for colorectal cancer liver
metastases before 2007.9,25,27,28 From most published series, it tran-
spires that over time survival after a liver resection of CRCLM
improves probably as a consequence of improved effectiveness of
modern chemotherapy regimens, improved peri-operative care,
better patient selection and more aggressive resections. The OS of
56 months in this study may also be influenced by the long
timeframe or modern chemotherapy regimens as well as addi-
tional treatment strategies in both patient groups with limited and
extended indication criteria and seems to support an aggressive
strategy towards CRCLM. From clinical practice, we observe that
extending the indications for liver resection of colorectal cancer
liver metastases renders more patients eligible. Our data show that
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extending the indications has its consequences for patients. It
leads to more major complications, a shorter OS and a shorter
DFS compared with patients with less extensive metastases. Major
complications often require surgical, endoscopic, or radiological
interventions. Although it may not be entirely legitimate to
compare the median OS of 41 months in patients eligible for liver
resection within extended indications to the median survival of
18–22 months in patients treated with chemotherapy alone, sur-
vival after a liver resection probably is substantially longer.29–32 The
increase in OS of approximately one and a half years compared
with the available literature data on outcome after palliative
chemotherapy alone, seems to justify the acceptance of a higher
complication rate after a resection.
Wiering et al.33 showed that quality of life recovered to baseline
within 3 months in patients undergoing a potentially curative liver
resection whereas a persistent decline in quality of life was dem-
onstrated in patients immediately treated with palliative chemo-
therapy alone. If patients turned out to be irresectable at
laparotomy, the quality of life was worst.34 It can therefore be
hypothesized that the occurrence of complications after liver
surgery with curative intent is an acceptable phenomenon for
patients. Futile laparotomies should be avoided by using optimal
pre-operative patient selection.
The morbidity and mortality results in the present study are
consistent with other recently published series,25,35 although com-
parison is hampered to some extent as definitions used for severe
or major morbidity vary across studies. In addition to standard-
ized definitions of complications, the use of a composite endpoint
for liver surgery-specific complications could enhance compa-
rability of published series.22
Strikingly, the occurrence of more severe complications did not
prolong the hospital LOS and did not lead to more readmissions.
It can be hypothesized that the expected prolonged hospital LOS
as a consequence of a higher percentage of major morbidity was
compensated by the introduction of the Enhanced Recovery after
Surgery (ERAS®) programme in our unit in 2005. A substantial
proportion of patients deceased in the first year after a partial
liver resection in both the extended indications and the limited
indications group. In this study, high age, a ASA score of 3 and
combined liver and colon resections proved to be risk factors for
a high 365-day mortality. Hence, it should be possible to reduce
post-operative mortality with better pre-operative patient selec-
tion. Unfortunately, our data, as well as other published data, did
not show predictive factors usable to select patients who were at
risk for mortality and consequently did not benefit from
surgery.36,37
All explorations/patients
N = 308/298
Limited indication criteria
N = 169/169
Extended indication criteria
N = 139/129
R0 resections
N = 157 (92.9%)
Recurrence
N = 77 (49.0%)
Hepatic: N = 45
Extrahepatic: N = 19
 Both: N = 13
Repeat resections
N = 22/21
Repeat resections
N = 0/0
Repeat resections
N = 13/11
Repeat resections
N = 2/1
Recurrence
N = 7 (58.3%)
Hepatic: N = 3
Extrahepatic: N = 3
 Both: N = 1
Recurrence
N = 54 (54.0%)
Hepatic: N = 23
Extrahepatic: N = 19
 Both: N = 12
Recurrence
N = 17 (58.6%)
Hepatic: N = 8
Extrahepatic: N = 7
 Both: N = 2
R1 resections
N = 12 (7.1%)
R0 resections
N = 100 (77.5%)
R1 resections
N = 29 (22.5%)
Figure 4 R1 resections, recurrence and repeat resections
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Compared with patients with limited indications, patients with
extended indications more often underwent an R1 resection. In
this series this did not lead to more repeat resections in the latter
group. Moreover, we showed that only 17% of the patients with a
R1 resection recurred at the level of the pathologically irradical
resection surface. This might be a result of the use of the CUSA
device (Integra LifeSiences, Plainsboro, NJ, USA), which does not
allow the pathologist to evaluate the actual resection surface, as
approximately 1 to 3 mm of hepatocytes disintegrate with the use
of this device. The consequence of this observation might be that
a close relation of metastases to vascular structures that cannot be
resected is not an absolute contraindication for resection. More-
over, an R0 resection rate of 77.5% and a median survival of 41
months as well as the cure percentage of 15.8% seems to justify the
use of extended indication criteria. As others have provided data
to suggest these patients have a good quality of life, it also seems
justified to be creative in future strategies to increase the resection
rate in patients with colorectal cancer liver metastases. Suggestions
might be to combine different treatment modalities that aim to
remove or destroy metastases while functional liver capacity is
maintained or enhanced. Open- or laparoscopic-resections com-
bined with ablation, irreversible electroporation, peri-operative
stereotactic radiotherapy or selective Internal Radio Therapy
(SIRT) with Ytrium-bound microspheres,38 may help to increase
the R0 resection rate and further improve survival with an accept-
able quality of life.
The new technique of in situ liver partition and portal vein
ligation for a two-stage hepatectomy with a short interval (ISLT or
ALPPS) seems promising but the current morbidity and mortality
of this procedure is still too high39–41
Strong points of this study are the selection of a series of patients
with extended indication criteria and a standardized complication
registration. Limitations are the relatively small sample size owing
to the single-centre study design, the large time period during
which the patients were included, the different peri-operative neo-
adjuvant or adjuvant chemotherapy strategies and the retrospec-
tive analysis of prospectively collected outcome data.
Conclusion
Liver resection for colorectal cancer liver metastases with
extended indication criteria seems justified. An R0 resection rate
of 77%, median 5-year overall survival of over 33% and cure in
16% of patients was achieved with acceptable post-operative mor-
tality and morbidity.
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